Bio-Techne Launches ExCellerate™ iPSC Expansion Medium
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) has launched ExCellerate™ iPSC Expansion Medium, designed for the expansion and maintenance of induced pluripotent stem cells (iPSCs). This new medium supports research and clinical applications in regenerative medicine, as it is animal component-free and includes essential growth factors for iPSC maintenance. It provides a consistent cell culture environment, allowing for reliable performance in generating homogeneous iPSCs. The launch signifies Bio-Techne's commitment to advancing innovative solutions for researchers in cell and gene therapies.
Positive
- Launch of ExCellerate™ iPSC Expansion Medium, expanding Bio-Techne's product portfolio.
- Medium is animal component-free, ideal for translational research in iPSC-based therapies.
- Supports robust iPSC expansion and maintenance, aiding in clinical applications.
Negative
- None.
Details
News Market Reaction – TECH
The recorded move for TECH in the trading session of this news was +1.45%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, Sept. 14, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) Bio-Techne announced the launch of a new medium for the expansion and maintenance of induced pluripotent stem cells (iPSCs) for use in both research and translational workflows. The ExCellerate™ iPSC Expansion Medium is the latest addition to Bio-Techne's comprehensive portfolio of products and services for Regenerative Medicine. It is designed to fit seamlessly into their offerings for stem cell workflows, including cell isolation, reprogramming, genome engineering, cell expansion, differentiation and characterization.
ExCellerate™ iPSC Expansion Medium is manufactured without using components derived from animal or humans, making it ideally suited for use in translational research to produce iPSC-based cell and gene therapies.
"Our vision is to develop innovative solutions that help researchers advance novel therapies that can change the lives of patients," said Dave Eansor, President, Protein Sciences Segment. "We are very excited to add our first iPSC medium to our portfolio. It is designed to support robust expansion and maintenance of high quality iPSCs and scales with the transition into clinical applications with human pluripotent stem cell-based therapies."
The formulation of ExCellerate™ iPSC Expansion Medium is animal component-free and contains the growth factors required for iPSC expansion and maintenance in a single, ready-to-use format. It is compatible with a variety of cell culture matrices and cell lines and provides a consistent cell culture environment to ensure reliable performance in generating large quantities of homogeneous, undifferentiated cells for any stage of research.
Please visit the Bio-Techne website for more information on the extensive portfolio of products and services for stem cell and organoid research and Cell and Gene Therapy.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Senior Director, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-launches-excellerate-ipsc-expansion-medium-301364809.html
SOURCE Bio-Techne Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.